Anonymous ID: 3c7ff0 May 2, 2020, 6:15 p.m. No.9005894   🗄️.is đź”—kun   >>5916 >>5926 >>5952 >>6022

Remdesevir negative press growing as Fraudci heads to Senate

 

even Bloomberg starting to bash Fraucci

 

"Remdesivir Trial Missed a Huge Opportunity

 

Rushing the drug through means we don’t know who it might help, or hurt.

 

The big Covid-19 news this week was a promising result from a new study of remdesivir, an anti-viral produced by Gilead Sciences. But lost in all the discussion of how well the drug works — an earlier study found it wasn’t helpful — was a tragic failure: Gilead missed its one shot at getting vital information on specifically which patients the drug could help.

 

The fact that a drug, any drug, seemed to fight Covid-19 is great news. But doctors also need information on whether older or younger patients were likely to benefit, for example, and how different pre-existing illnesses might tip the risk-benefit ratio. Instead, we got what Memorial Sloan-Kettering Cancer Center physician and epidemiologist Peter Bach calls the bare minimum of information — just enough to get the drug over the hurdles needed for approval. Now there are ethical barriers to the kinds of placebo-controlled studies needed to learn more.

 

There’s a tremendous heterogeneity in patients — in age, health conditions, symptoms, viral load and genetics. More studies of remdesivir would surely have saved lives by revealing whether remdesivir helps only a subset of patients, and whether it might even be toxic to others. (snip) "

 

sauce:

https://www.bloomberg.com/opinion/articles/2020-05-01/coronavirus-gilead-s-remdesivir-trial-missed-a-huge-opportunity?srnd=opinion&sref=ZtdQlmKR